Novo Nordisk A/S (NVO)
Pre-market:
| Previous close | 129.21 |
| Open | 127.94 |
| Bid | 120.62 x 1200 |
| Ask | 121.24 x 800 |
| Day's range | 123.83 - 127.94 |
| 52-week range | 75.56 - 138.28 |
| Volume | |
| Avg. volume | 4,903,027 |
| Market cap | 559.691B |
| Beta (5Y monthly) | 0.19 |
| PE ratio (TTM) | 46.45 |
| EPS (TTM) | 2.67 |
| Earnings date | 03 May 2024 |
| Forward dividend & yield | 1.37 (1.06%) |
| Ex-dividend date | 22 Mar 2024 |
| 1y target est | 144.38 |
- Yahoo Finance Video
Novo Nordisk slides while Moderna pops: Tale of two pharma stocks
Pharmaceutical stocks Novo Nordisk (NVO) and Moderna (MRNA) are trending in opposite directions following their earnings reports. Despite topping Wall Street's profit expectations, Novo Nordisk shares are sinking as the company fell short of estimates for its popular GLP-1 weight-loss drug, Wegovy. Meanwhile, Moderna is on the rise even after reporting first quarter losses. Moderna's growth is largely due to an uptick in coronavirus boosters and an expansion into the Brazillian market. For more expert insight and the latest market action, click here to watch this full episode of Market Domination. This post was written by Melanie Riehl
Yahoo FinanceNovo Nordisk sales up 26% driven by GLP-1s, misses 11% on Wegovy
Novo Nordisk CEO Lars Jørgensen tells Yahoo Finance the company is confident about a robust GLP-1 sales year despite missing Wall Street estimates.
BloombergNovo Slides as Amgen Fuels Obesity Drug Competition Fears
(Bloomberg) -- Novo Nordisk A/S shares fell as a US rival’s comments on an experimental obesity drug gave rise to concerns about potential new competition in the rapidly growing field.Most Read from BloombergSaudi Arabia Steps Up Arrests Of Those Attacking Israel OnlineApple Rallies on Upbeat Forecast, Record-Setting BuybackTurkey Confirms All Trade Halt With Israel Over War in GazaHuawei Secretly Backs US Research, Awarding Millions in PrizesTrump Auditions VP Picks Before Wealthy Donors in Pal
